Skip to main content
    S

    Sagimet Biosciences Inc. Series A Common Stock (SGMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.13
    -0.09 (-0.88%)

    Market Cap: $735.18M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Sagimet Biosciences Inc. Series A Common Stock (SGMT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Sagimet Biosciences Inc. Series A Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$51.04M, operating cash flow was -$45.65M and free cash flow was -$45.65M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$19.15M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $56.89M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$2.00MN/A100.0%-1537.0%-1393.8%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$0$0$2.00M$0$0$0$0
    Cost of revenue$0$0$0$0$134.00K$124.00K$88.00K
    Gross profit$0$0$2.00M$0-$134.00K-$124.00K-$88.00K
    Research and development$39.05M$38.44M$19.78M$24.92M$19.34M$8.18M$8.39M
    Operating income-$56.89M-$54.45M-$30.74M-$31.05M-$23.72M-$11.40M-$14.16M
    Net income-$51.04M-$45.57M-$27.88M-$30.50M-$24.44M-$11.37M-$14.26M
    EBITDAN/AN/AN/AN/A-$23.72M-$11.40M-$14.11M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating income-$21.57M-$15.82M-$11.71M-$10.77M-$14.33M-$11.93M-$19.86M-$18.20M-$16.90M-$10.59M-$8.77M-$9.47M
    Net income-$19.15M-$13.95M-$10.65M-$9.57M-$12.91M-$10.39M-$18.18M-$16.20M-$14.62M-$8.12M-$6.63M-$8.15M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $78.00K by $34.94M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$116.48M$160.26M$96.72M$33.03M$59.03M$68.96M$11.16M
    Current assets$116.40M$152.77M$96.65M$32.79M$58.66M$68.74M$10.81M
    Cash and equivalents$35.02M$75.84M$75.14M$158.00K$56.73M$68.70M$10.21M
    Total liabilities$5.10M$4.45M$5.65M$5.36M$217.29M$204.87M$136.47M
    Short-term debt$78.00K$78.00K$65.00K$133.00K$124.00K$145.00K$130.00K
    Shareholder equity$111.38M$155.81M$91.06M-$186.95M-$158.26M-$135.91M-$125.31M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$282.09M$263.43M$107.75M$116.48M$128.40M$137.41M$146.17M$160.26M$174.78M$189.02M$194.53M$96.72M
    Total liabilities$39.91M$7.28M$5.30M$5.10M$9.15M$7.25M$7.18M$4.45M$4.09M$5.73M$4.51M$5.65M
    Cash and equivalents$110.96M$165.90M$36.63M$35.02M$32.50M$42.33M$64.72M$75.84M$77.01M$95.96M$176.78M$75.14M
    Shareholder equity$242.18M$256.15M$102.46M$111.38M$119.25M$130.16M$138.99M$155.81M$170.68M$183.29M$190.02M$91.06M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$45.65M-$42.44M-$23.77M-$24.49M-$21.71M-$10.42M-$10.55M
    Free cash flow-$45.65M-$42.44M-$23.77M-$24.49M-$21.71M-$10.42M-$10.55M
    Investing cash flow$4.56M-$61.68M$12.58M-$32.01MN/A$20.00K-$27.00K
    Financing cash flow$275.00K$104.82M$86.17M-$73.00K$9.74M$68.89M$18.48M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$12.11M-$11.10M-$8.61M-$11.83M-$10.18M-$9.10M-$14.54M-$11.02M-$19.57M-$5.63M-$6.21M-$7.08M
    Free cash flowN/AN/A-$8.61M-$11.83M-$10.18M-$9.10M-$14.54M-$11.02M-$19.57M-$5.63M-$6.21M-$7.08M
    Last 12 quarters

    Frequently Asked Questions About SGMT

    What is Sagimet Biosciences Inc. Series A Common Stock's annual revenue?

    Sagimet Biosciences Inc. Series A Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Sagimet Biosciences Inc. Series A Common Stock profitable?

    No. Sagimet Biosciences Inc. Series A Common Stock reported net income of -$51.04M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does SGMT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$45.65M minus capital expenditures of $0 produced free cash flow of -$45.65M.

    How much debt does Sagimet Biosciences Inc. Series A Common Stock have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $78.00K and cash and equivalents of $35.02M.